I

InDex Pharmaceuticals Holding AB
STO:FLERIE

Watchlist Manager
InDex Pharmaceuticals Holding AB
STO:FLERIE
Watchlist
Price: 45.3 SEK 1.59% Market Closed
Market Cap: 3.5B SEK
Have any thoughts about
InDex Pharmaceuticals Holding AB?
Write Note

InDex Pharmaceuticals Holding AB
Gross Profit

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

InDex Pharmaceuticals Holding AB
Gross Profit Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Gross Profit CAGR 3Y CAGR 5Y CAGR 10Y
I
InDex Pharmaceuticals Holding AB
STO:FLERIE
Gross Profit
-kr92m
CAGR 3-Years
-145%
CAGR 5-Years
-361%
CAGR 10-Years
N/A
Calliditas Therapeutics AB
STO:CALTX
Gross Profit
kr1.5B
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Camurus AB
STO:CAMX
Gross Profit
kr1.6B
CAGR 3-Years
51%
CAGR 5-Years
89%
CAGR 10-Years
N/A
S
Swedencare AB (publ)
STO:SECARE
Gross Profit
kr1.4B
CAGR 3-Years
80%
CAGR 5-Years
75%
CAGR 10-Years
N/A
IRLAB Therapeutics AB
STO:IRLAB A
Gross Profit
-kr122.7m
CAGR 3-Years
-23%
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Moberg Pharma AB (publ)
STO:MOB
Gross Profit
kr0
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
No Stocks Found

InDex Pharmaceuticals Holding AB
Glance View

Market Cap
3.5B SEK
Industry
Pharmaceuticals

InDex Pharmaceuticals Holding AB engages in the development of drugs for the treatment of diseases such as inflammation and cancer. The company is headquartered in Solna, Stockholm and currently employs 6 full-time employees. The company went IPO on 2016-10-11. The firm is focused in pharmaceuticals development. The firm's drug candidate is cobitolimod that helps in ulcerative colitis treatment. In addition, the Company develops a platform of patent protected substances, DNA based ImmunoModulatory Sequences (DIMS), that helps in the treatment of various immunological diseases. The firm also offers diagnostic kit DiBiCol, which is a PCR-based method that monitors seven biomarkers specific for ulcerative colitis or Crohn’s disease from a single colonic biopsy. InDex Pharmaceuticals Holding AB operates as a parent for InDex Pharmaceuticals AB and InDex Diagnostics AB. Among the Company's shareholders are SEB Venture Capital, Industrifonden and NeoMed Management.

FLERIE Intrinsic Value
5.85 SEK
Overvaluation 87%
Intrinsic Value
Price
I

See Also

What is InDex Pharmaceuticals Holding AB's Gross Profit?
Gross Profit
-92m SEK

Based on the financial report for Sep 30, 2024, InDex Pharmaceuticals Holding AB's Gross Profit amounts to -92m SEK.

What is InDex Pharmaceuticals Holding AB's Gross Profit growth rate?
Gross Profit CAGR 5Y
-361%

The average annual Gross Profit growth rates for InDex Pharmaceuticals Holding AB have been -145% over the past three years , -361% over the past five years .

Back to Top